The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
APAC to see a reduction in imported surgical robotics
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Subscribe To Our Newsletter & Stay Updated
